Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
Workplace testing uses cheap, fast immunoassay panels that ignore peptides entirely
Higher (10 g/kg) dosage was effective either after a single or daily regimen, whereas lower (10 ng/kg) dosage, previously ineffective given as a single application, becomes efficacious when applied as a daily regimen
Its a foundational tool for anyone looking to heal connective tissue damage or improve skin integrity
This is a great multipurpose IV with many uses because of its unique combination of vitamins and minerals that ease common symptoms such as fatigue and low energy levels
PubMed Central, Andersson, Cecilia, et al
